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Abstract
Survivin, a member of the inhibitor of apoptosis (IAP)
gene family, plays an important role in both the
regulation of cell cycle and the inhibition of apopto-
sis, and is frequently overexpressed in many tumor
types. In neuroblastomas, the expression of survivin
correlates with a more aggressive and histologically
unfavorable disease. Survivin is predominantly a
cytoplasmic protein that is expressed in a cell cycle-
dependent manner, increasing in the G2/M phase of the
cell cycle followed by a rapid decline in the G1 phase.
Recently, the role of survivin in resistance to chemo-
therapy has become an area of intensive investigation.
In this study, we demonstrate a phase-specific resist-
ance due to survivin in staurosporine (STS)–induced
apoptosis in the human neuroblastoma cell line SK-N-
MC. G2/M-arrested cultures show an upregulation of
survivin expression and are more resistant, whereas
G1-phase cells that show decreased levels of survivin
are more sensitive to apoptosis. Localization studies
revealed differences in the distribution of survivin in
two synchronized populations, with G1 cells having
weakly positive staining confined to the nucleus, in
contrast to G2/M cells that depicted amore uniform and
intense expression of survivin throughout the cell. In
our experimental system, STS induced apoptosis
through the mitochondrial–caspase 9–mediated path-
way. Retention of survivin in G1 cells by inhibition of
the ubiquitin–proteosome pathway or inhibition of
caspase 9 protected the cells against apoptosis. Our
data suggest that survivin exerts its antiapoptotic
effect by inhibiting caspase 9 activity, an important
event in STS-mediated apoptosis. In context with cell
cycle–dependent responses to chemotherapy, the
data from this study suggest the possibility of exploit-
ing the survivin pathway for inducing apoptosis in
tumor cells.
Neoplasia (2004) 6, 29–40
Keywords: Survivin, caspase 9, G2/M, staurosporine, neuroblastoma.
Introduction
Apoptosis is a ‘‘default’’ process intrinsic to all cells, which is
abrogated by the provision of survival signals within cells
[1]. Chemotherapeutic drugs induce damage at a number of
different loci, and the balance between the proapoptotic and
survival signals determines cellular fate [2]. Intensive research
has led to the identification of several proteins such as the Bcl-2
family, HSP27 and HSP70, and inhibitor of apoptosis (IAP)
family proteins, which not only render tumor cells resistant to
apoptosis but also promote tumorigenesis [3].
Survivin, a 16.5-kDa protein, is present as a homodimer
in vivo [4]. It is one of the eight proteins of the human IAPs that
contain at least one copy of the baculovirus inhibitor of apo-
ptosis repeats (BIR) domain, expressed only in dividing cells
and therefore is predicted to be a bifunctional protein that both
suppresses apoptosis as well as regulates cell division [5,6].
Survivin expression is considered to be the most tumor-specific
of all human gene products [7] and is reported to be highly
expressed in a number of tumor types especially neuroblasto-
ma, colorectal carcinomas, and gastric carcinomas, and corre-
lates with poor prognosis of the disease [7–9]. Survivin
contains a G1 transcriptional repressor element within
its promoter. The survivin promoter also exhibits typical
M-phase–inducible transactivation, suggesting that survivin
is a cell cycle–regulated molecule, which is repressed in the
G1 phase and is highly expressed in the G2/M phase. It
associates with the mitotic spindle through its C-terminal
domain [10] and the role of survivin during mitosis involves
the regulation of microtubule assembly and the functional
formation of a normal bipolar apparatus [6].
The cell cycle–specific regulation of survivin in tumor cells
suggests that the protein contributes to the regulation of
apoptosis during cell proliferation. Reports on the interaction
between survivin and caspases have been contradictory. Al-
though few studies have suggested that survivin binds and
suppresses caspases 3, 7, and 9, others have failed to dem-
onstrate a direct effect on these proteases [11–14]. Phos-
phorylation of survivin at threonine 34 is required for the
interaction of survivin with caspases 3, 7, and 9 in vitro. A
mutation from this threonine to alanine (T34A) can induce the
release of cytochrome c from the mitochondria, leading to
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apoptosis. The only kinase reported to date that phoshor-
ylates survivin is cdc-2/CDK1, a cyclin-dependent kinase
that is active only at certain stages of the cell cycle. This
kinase has been coimmunoprecipitated with survivin during
mitosis, indicating a direct physical interaction between the
two for phosphorylation of survivin [15]. One of the important
features for anticancer drug treatment to be effective is that
the cancer cells must be sensitive to the effects of the drug
before resistance emerges. Cell cycle–specific chemother-
apy drugs work at specific points in the cell cycle. For
instance, paclitaxel (Taxol; Bristol-Myers Squibb Oncology/
Immunology Division, Princeton, NJ) a common chemother-
apeutic agent used in breast cancer, works at the G2/M
stage. Cell cycle–dependent resistance is an emerging
concept in combination sequential chemotherapy [16]. Al-
though survivin is specifically present in G2/M cells, its role in
protecting cell populations in this phase to chemotherapeutic
agents has not been reported. In this study, we demonstrate
the differential sensitivity of the G1- and G2/M-synchronized
human neuroblastoma cell line SK-N-MC to Staurosposine
(STS)-induced apoptosis, and suggest a critical role for
survivin in imparting resistance in the G2/M population. We
observed that STS induces apoptosis primarily through the
mitochondrial pathway by activating caspase 9 as the prime
initiator caspase. Survivin appears to exert its phase-specific
antiapoptotic effect by inhibiting this caspase 9 activity.
Materials and Methods
Cell Line and Culture
The human neuroblastoma cell line SK-N-MC was pro-
cured from the American Type Culture Collection (ATCC;
Rockville, MD) and maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% heat-
inactivated fetal bovine serum (Gibco BRL, Carlsbad, CA)
at 37jC in a humidified atmosphere of 5% CO2 and 95% air.
Cell Synchronization and Treatment
SK-N-MC cells were seeded at a density of 0.5  106
cells/ml and cultured for 24 hours before synchronization
with 5 mM aphidicolin (Sigma, St. Louis, MO) for 12 hours to
arrest them in the G1 phase, or with 30 nM nocodazole
(Calbiochem, La Jolla, CA) for 12 hours to arrest the cells in
the G2/M phase. The cells were then treated for 12 hours
with 100 nM STS (Sigma) to induce apoptosis in synchro-
nized and unsynchronized cells.
Cell Cycle Analysis
Cell cycle analysis for synchronized cells was monitored as
DNA profiles after staining with propidium iodide. Cells were
harvested, washed with 1  phosphate-buffered saline
(PBS), fixed in 70% chilled ethanol at 4jC for 10 minutes,
hydrolyzed with 5 mg/ml ribonuclease A for 20 minutes, and
stained with 50 mg/ml propidium iodide. DNA content was
determined on a flow cytometer (FACS Vantage BD, San
Jose, CA) equippedwith a 488-nm argon laser and populations
in cell cycle phases were quantified using MODFIT software.
TUNEL Assay
Terminal deoxynucleotidyl transferase-mediated dUTP
nick-end labeling (TUNEL) assay was used to assess the
apoptosis induced by STS and was measured by FragEL
DNA fragmentation detection kit (Oncogene Research) as
per the manufacturer’s instructions. Briefly, the cells were
fixed with 70% chilled ethanol at 4jC for 10 minutes, washed
with 1  TBS, rehydrated for 30 minutes in 1  TBS, equil-
ibrated for 30 minutes with 1  equilibration buffer, and fur-
ther incubated at 37jC for 2 hours with the labeling reaction
mixture containing labeling reaction buffer, fluorescein iso-
thiocyanate (FITC)-tagged dUTP, and TdT enzyme. The
cells were washed and acquired on a flow cytometer
equipped with a 488-nm argon laser. The extent of FITC
positivity was used as a parameter to quantify the apoptosis
induced by STS.
Study of Mitochondrial Membrane Potential (MMP)
Changes in the MMP of SK-N-MC cells were studied by
the MitoCapture apoptosis detection kit (Oncogene Re-
search), as per the manufacturer’s instructions. The assay
uses a fluorescence-based method utilizing the ability of the
MitoCapture dye to differentially stain healthy and apoptotic
cells. SK-N-MC cells were washed in 1  PBS and incubat-
ed at 37jC for 20 minutes in the MitoCapture reagent
(1:1000 dilution). The cells were washed and resuspended
in incubation buffer and acquired on the FL2 channel (585/
590) of a flow cytometer equipped with a 488-nm argon laser.
A decrease in red fluorescence intensity was considered as a
function of the breakdown in membrane potential. The cell
population in the region of decreased fluorescence was
quantified as apoptotic cells in untreated and treated cells.
Caspase 9 Activity and Inhibition Assay
The activation of caspase 9 in SK-N-MC cells treated with
STS was assessed using caspase 9 colorimetric assay kit
(Oncogene Research). SK-N-MC cells were seeded at a
density of 3  104 cells/100 ml in a 96-well plate for 24 hours.
After the specified time of treatment, the spent medium was
aspirated and 50 ml of assay buffer with fresh 1 mM DTT was
added to the wells and incubated at 37jC for 30 minutes
followed by the incubation with caspase 9 colorimetric sub-
strate LEDH-pNa for 2 hours. The release of pNa due to the
cleavage of LEDH by active caspase 9 was read at 405 nm
using a microplate reader (Molecular Devices, Sunnyvale,
CA). Similar experiments were performed with cells treated
for 1 hour prior to STS treatment with Z-LEDH-FMK (20 mM),
a cell-permeable inhibitor of caspase 9, and activity was
determined.
Inhibition of Ubiquitin–Proteasome Pathway
SK-N-MC cells were treated with 10 mM proteasome
inhibitor MG132 for 2 hours prior to G1 synchronization
followed by STS treatment.
Western Blot Analysis
SK-N-MC cells (0.5  106 cells) were harvested, washed
with 1  PBS, and lysed in 50 ml of 1  Lamelli’s sample
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buffer. The resultant lysate was clarified and centrifuged
at 22,000g for 10 min. The supernatant was aspirated and
10 ml was resolved on a denaturating polyacrylamide gel
[10% for poly (ADP ribose) polymerase (PARP); 15% for Bcl-
2, bax, survivin, and cdc-2] followed by electroblotting onto
PVDF membrane in 20 mM sodium phosphate buffer, pH
6.8, at 100 mA per gel for 1 hour. The membrane was
blocked with 5% BSA in Tris saline Tween (TST) buffer
(20 mM Tris, 0.5 M NaCl, and 0.05% Tween 20) for 1 hour
at room temperature (RT). The blots were incubated for
2 hours at RT in primary antibodies: anti–Bcl-2, anti-BclXL,
anti-PARP (Santa Cruz Biotechnology, San Diego, CA), anti-
cdc2 (Pharmingen BD, San Diego, CA), antisurvivin (Chem-
icon, Temecula, CA), and antiactin antibody (Sigma), and
diluted in TST buffer as recommended by the manufacturers.
The blots were washed with TST buffer followed by incuba-
tion with appropriate HRP-labeled secondary antibodies
(BioRad, Hercules, CA) at 1:10,000 dilution for 1 hour at
RT. The membrane was washed with TST buffer and the
probed proteins were detected by the Enhanced Chemilumi-
nescence System (Amersham, Buckinghamshire, UK)
according to the manufacturer’s instructions. The blots were
stripped and reprobed for actin. The expression of the
proteins was normalized with respect to actin.
Immunostaining for Flow Cytometry
Immunostaining was performed to monitor the cell cycle–
dependent expression of survivin by flow cytometry. SK-N-
MC cells, synchronized in G1 and G2/M phases, were fixed
with 70% chilled ethanol for 10 minutes at 4jC. The ethanol
was washed with 1  PBS and the cells were incubated with
1 mg of antisurvivin antibody (Santa Cruz Biotechnology)
diluted in 1  PBS containing 0.5% BSA for 1 hour at 4jC
followed by incubation with 1 mg of FITC-labeled secondary
antibody (Pharmingen BD) at 4jC for 1 hour. The cells were
washed and resuspended in PBS containing 5 mg/ml RNase
A and 50 mg/ml propidium iodide. Bivariant analysis was
performed to determine the survivin-positive cells with re-
spect to the DNA content.
Immunostaining for Confocal Microscopy
SK-N-MC cells were seeded at a density of 0.35  104
cells/ml per coverslip (Sigma), grown for a period of 24
hours, and synchronized as described earlier. The cells were
fixed with freshly prepared 3.7% chilled paraformaldehyde
(ICN, Aurora, OH) for 10 minutes, washed with 1  PBS
(Life Technologies, Frederick, MD) and permeabilized with
cold 0.02% Triton X-100 for 30 seconds. The cells were
incubated overnight at 4jC with antisurvivin antibody (Santa
Cruz Biotechnology) and antitubulin antibody (Sigma) diluted
in 1  PBS containing 0.5% BSA. The coverslips were
washed with 1  PBS and incubated with appropriate
secondary antibodies (DAKO, Glostrup, Denmark) labeled
with FITC and tetramethyl rhodamine isothiocyanate
(TRITC; diluted 1:50) at 4jC for 1 hour. The expression of
survivin with respect to the presence of tubulin was observed
by a confocal laser scanning microscope fitted with a
488-nm/540-nm argon laser (Carl Zeiss, Jena, Germany)
at an image magnification of  63 objective.
Transfection with Antisense Oligonucleotides
SK-N-MC cells were transfected with phosphorothioate
antisense oligonucleotides (GenoMechanix, Alachua, FL)
against survivin with Lipofectamine 2000 (Life Technologies)
as per the manufacturers’ instructions. Briefly, 0.4  106
cells were transfected with 212 nM and 424 nM survivin
antisense 5V CCCAGCCTTCCAGCTCCTTG 3V 2 ml of Lipo-
fectamine 2000 for 6 and 9 hours, and the expression of
survivin was assessed by Western blot analysis. Cells trans-
fected with scrambled sequence 5V GCACCTAGTCT-
CCCTGCACC 3V served as controls.
Semiquantitative Reverse Transcription Polymerase Chain
Reaction (RT-PCR)
Total RNA was extracted from control and treated SK-
N-MC cells using the Trizol method. cDNA was prepared
from 3 mg of total RNA by reverse transcription with MMLV-
RT enzyme (Life Technologies) at 37jC for 60 minutes.
The survivin transcript of 450 bp was amplified from the
cDNA using recombinant Taq polymerase (Life Technolo-
gies). b-Actin was used as an internal control.
The primers used were:
Survivin: Forward—5V AATAAATGGATCCATGGGTGC-
CCCGACGTTGCCCAGC 3V
Reverse—5V CTAAGCTTTCAATCCATGGCAG-
CAAGC 3V
b-Actin: Forward—5V GTGGGGCGCCCCAGGCACCA 3V
Reverse—5V CTCCTTAATGTCACGCACGATTTC 3V.
Statistical Analysis
The data were analyzed with Sigma Stat software (Jandel
Scientific, San Rafael, CA). Treated cells and the corre-
sponding controls were compared using one-way analysis
of variance (ANOVA) followed by Student-Newman-Kuels
test. P < .05 was considered significant.
Results
Differential Sensitivity of SK-N-MC Cells Arrested in G1 and
G2/M Phases to STS-Induced Apoptosis
SK-N-MC cells were synchronized with aphidicolin in the
G1 phase or with nocodazole in the G2/M phase. Unsyn-
chronized cells had a cell cycle distribution pattern of 63.54%
cells in the G1 phase, 24.72% cells in the S phase, and
11.83% cells in the G2/M phase. Arrest of SK-N-MC cells in
the G1 phase with aphidicolin showed an accumulation of
84.86% cells in the G1 phase, 15.32% cells in the S phase,
and no cells in the G2/M phase. Arrest in the G2/M phase
with nocodazole resulted in an accumulation of 67.16% cells
in the G2/M phase and 29.15% and 3.69% cells in the S and
the G1 phases, respectively (Figure 1A). We then examined
the induction of apoptosis in the enriched populations treated
with 100 nM STS for 6 and 12 hours by TUNEL assay. It was
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Figure 1. Differential sensitivity of SK-N-MC cells arrested in G1 and G2/M phases to STS-induced apoptosis. (A) Cell cycle distribution of synchronized cells
assessed by flow cytometry. SK-N-MC cells were synchronized with 5 M aphidicolin and 30 nM nocodazole in the G1 and G2/M phases, respectively. A
representative histogram of unsynchronized, G1- and G2/M-arrested populations is shown and the data from three similar experiments are presented as stacked
bars. (B) Selective sensitivity of the arrested cell populations to undergo apoptosis induced by STS with 6 and 12 hours of treatment assessed by TUNEL assay. G1
cells were more susceptible to STS as compared to the G2/M population. The data are the means of three independent experiments. (C) Expression of PARP by
Western blotting in unsynchronized and synchronized cells treated with STS for 12 hours. Densitometric analysis of band intensities normalized with -actin is
shown in the histogram.
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observed that with 6 hours of STS treatment, G1-arrested
cells showed 18.67% apoptosis that increased to 38.86% by
12 hours in comparison with unsynchronized controls, which
had 3.18% apoptosis at 6 hours and 20.64% at 12 hours. The
G2/M population treated with STS showed no significant
apoptosis, with an apoptotic population of 3.18% at 6 hours
and 4.93% at 12 hours of treatment. These results indicated
that G2/M cells are more resistant to STS-mediated apopto-
sis as compared to the G1 phase cells and unsynchronized
control populations (Figure 1B ). Cleavage of poly(ADP ri-
bose) polymerase (PARP) is considered a hallmark of the
apoptotic process. We therefore examined PARP cleavage
in STS-treated cell populations. The full-length and cleaved
PARP was normalized to the loading control, actin. We
observed that the native 116-kDa PARP was cleaved to its
89-kDa signature cleavage product in the G1-arrested and
the unsynchronized cell populations. The cleavage of PARP
was more pronounced in G1 cells with increased intensity
of the cleaved band and a corresponding decrease in the
native protein. No significant PARP cleavage was detected
in G2/M-arrested cells (Figure 1C ).
Antiapoptotic Molecule Survivin Is Expressed in a Cell
Cycle–Dependent Manner
Because a significant difference in response to STS
between the G1 and G2/M phase cells was observed, we
monitored the expression of Bcl-2 and BclXL, antiapoptotic
molecules known to play an important role in protecting
cells against mitochondrial-dependent apoptosis induced
by STS. The expression of survivin was also monitored,
as it is an antiapoptotic molecule that is regulated in a cell
cycle–dependent manner. We observed no significant
difference in the expression of Bcl-2 and BclXL in the
STS-treated synchronized and unsynchronized cells com-
pared to their respective untreated controls. However, a
remarkable difference in the expression of survivin was
observed. In comparison with unsynchronized cells,
G1-arrested populations showed a 93.18% decrease in
survivin expression, whereas G2/M-arrested cells showed
a 52.75% increase that was sustained with STS treatment
(Figure 2A). Cell cycle–dependent expression of survivin
was confirmed in SK-N-MC cells by dual staining with
antibody specific for survivin and propidium iodide for
DNA, and analyzed by flow cytometry. Percent positivity
was scored in comparison to the isotype control and 5%
positivity was set as cutoff. The expression of survivin
was observed to be restricted to the G2/M phase
(Figure 2B), corroborating the results of our immunoblot
analysis. Next we analyzed the subcellular localization of
survivin with respect to tubulin by confocal microscopy.
We observed a moderate amount of survivin in unsyn-
chronized cultures that was localized in the nucleus,
corresponding to green fluorescence. Cells arrested in
G1 phase exhibited a low expression of survivin that was
localized in the nucleus. In a striking contrast, survivin
was distributed uniformly in G2/M cells and colocalized
with tubulin, as evident from the yellow fluorescence in
the cytosol (Figure 2C ), which may be necessary for
function as an antiapoptotic molecule.
Expression of cdc-2 Occurs in a Cell Cycle–Dependent
Manner and Correlates with the Expression of Survivin
We observed that survivin was differentially expressed in
the two phases of the cell cycle. The key requirement for the
function of survivin is its phosphorylation at threonine 34 by
CDK1. Therefore, the expression of cdc-2 was studied by
Western blotting. We observed a 3.14-fold increase in the
levels of cdc-2 in G2/M-arrested cells (Figure 2D). This
expression pattern correlated with the expression of survivin.
Thus, in accordance with previous reports, it is possible that
cdc-2 interacts with survivin during the G2/M phase to
phosphorylate and impart antiapoptotic property.
Downregulation of Survivin Sensitizes Cells to
STS-Mediated Apoptosis
We reasoned that if survivin was responsible for the
resistance to apoptosis induced by STS in G2/M-synchro-
nized cells, then downregulation of survivin should affect the
sensitivity of these cells to STS. SK-N-MC cells were trans-
fected with 212 and 424 nM phosphorothioate-modified
antisense survivin oligonucleotides for 6 and 9 hours fol-
lowed by treatment with STS for 3 hours. The expression of
survivin was monitored by Western blot analysis and the
extent of PARP cleavage was evaluated as an indicator of
apoptosis. We observed a 76.47% and 77.62% decrease in
survivin expression in cells transfected with 212 nM survivin
antisense oligonucleotide for 6 and 9 hours, respectively. A
near-complete inhibition of survivin expression with 424 nM
survivin antisense was observed (Figure 3A). Cleavage of
PARP was observed within 3 hours of STS treatment in
transfected cells with a four-fold increase in the sensitivity of
cells to STS (Figure 3B). Cells transfected with scrambled
survivin sequence did not show any apoptosis (data not
shown). These data highlight the importance of survivin as
a molecule mandatory for the survival of cells and enables
them to evade the apoptotic insult. The antisense-trans-
fected control cells not treated with STS did not show any
inherent apoptosis as evaluated by trypan blue staining (data
not shown) and propidium iodide staining (Figure 3C), indi-
cating that a decrease in survivin expression alone does not
lead to the apoptosis of cells.
Induction of Apoptosis by STS in SK-N-MC Cells Is Primarily
through the Mitochondrial–Caspase 9 Pathway
During apoptosis, the mitochondrial inner transmem-
brane potential (DwM) is frequently disrupted due to the
formation of permeability transition pores, or the insertion
of proapoptotic proteins such as Bid or Bax in the mito-
chondrial membrane. We therefore examined the effect of
STS on the membrane potential of SK-N-MC cells by
staining with a cationic dye using the MitoCapture apo-
ptosis detection kit. This cationic dye accumulates and
aggregates in the mitochondria of healthy cells and emits
an orange red fluorescence that is analyzed by flow
cytometry. A decrease in the intensity of red fluorescence
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Figure 2. Expression of survivin in a cell cycle–dependent manner. (A) Expression of antiapoptotic molecules, Bcl-2, BclXL, and survivin in untreated and STS-
treated synchronized cell populations studied by immunoblotting. (B) Expression of survivin in unsynchronized and synchronized cell populations with respect to
the cell cycle analyzed by flow cytometry. FL2-A on the X-axis represents DNA content, and FL1-H on the Y-axis denotes fluorescence intensity for survivin
staining. (C) Localization of survivin in synchronized cells studied by immunostaining and visualized under a confocal laser scanning microscope. Cells were
stained for survivin (green) and tubulin (red), and colocalization of survivin and tubulin is seen as yellow fluorescence in merged images. (D) Immunoblot analysis
for cdc-2 expression performed in synchronized cells. Western blots were normalized against actin used as loading control. The bar graphs are representatives for
the densitometric analysis of survivin (a) and cdc-2 (b).
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is considered a parameter for breakdown in membrane
potential and hence a measure of apoptotic population. A
3.1-fold and 6.9-fold decrease in membrane potential
was observed in unsynchronized and G1-arrested cells,
respectively, compared to G2/M-arrested cells, which
showed no breakdown of membrane potential with STS
treatment. On this criterion, 69.22% cells were observed to
undergo apoptosis with STS treatment in unsynchronized
Figure 3. Downregulation of survivin sensitizes cells to STS-mediated apoptosis. (A) SK-N-MC cells were transfected with phosphorothioate antisense
oligonucleotides to survivin (212 and 424 g) for 6 and 9 hours and the expression of survivin was analyzed by Western blot analysis using antisurvivin antibody.
The bar graph represents densitometric analysis of the expression of survivin normalized against the loading control -actin. (B) Western blot analysis of full-length
PARP (116 kDa) and cleaved PARP (DPARP) in untreated and STS-treated (3 hours) SK-N-MC cells transfected with survivin antisense oligonucleotides. (C)
Flowcytometry analysis of untreated SK-N-MC cells transfected with survivin antisense stained with propidium iodide to study the DNA profile. Marker denotes
hypodiploidy region for apoptosis population.
Figure 2. (Continued)
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populations, which increased to 86.22% in G1-arrested cells.
There was no difference in the apoptosis between control
and STS-treated G2/M-arrested cultures (Figure 4A). Cas-
pase 9 is the key initiator caspase that is activated during
mitochondrial-dependent apoptosis. We therefore deter-
mined caspase 9 activity in SK-N-MC cells treated with
STS for 6 hours by caspase 9 colorimetric assay that reads
the absorbance of pNa released on cleavage of the substrate
LEDH-pNa by active caspase 9. There was no difference in
the basal levels of caspase 9 activity between the unsyn-
chronized population and cells arrested in different phases,
but on treatment with STS, caspase 9 activity increased
with fold increases of 2.1 and 2.6 in unsynchronized and
G1-arrested cells, respectively. However, no increase in cas-
pase 9 activity was detectable in the G2/M-arrested popula-
tion treated with STS (Figure 4B).
Inhibition of Caspase 9 Activity Abrogates Apoptosis in
STS-Treated SK-N-MC Cells
As treatment of SK-N-MC cells with STS resulted in
breakdown of membrane potential and activation of caspase
9, further experiments were performed to investigate the role
of caspase 9 in STS-induced apoptosis in SK-N-MC cells.
Cells were treated with the irreversible cell-permeable cas-
pase 9 inhibitor Z-LEDH-FMK (20 mM) an hour prior to
treatment with STS for 6 hours and caspase 9 activity was
determined by a colorimetric assay. A 60.1% and 44.0%
decrease in caspase 9 activity was observed in G1-arrested
and unsynchronized cells, respectively, when treated with
STS in the presence of caspase 9 inhibitor (Figure 5A). We
further studied the effect of the inhibition of caspase 9 activity
on the extent of apoptosis induced by STS. The cleavage of
PARP was monitored for the apoptosis induced in SK-N-MC
cells treated with STS in the presence of 20 mM caspase 9
inhibitor. We observed that the inhibition of caspase 9 activity
Figure 4. Breakdown in MMP and caspase 9 activity. (A) Analysis of
mitochondrial permeability transition after treatment of synchronized SK-N-
MC cells with STS for 6 hours. Cells were stained with mitotracker dye and
analyzed by flowcytometry. The data were acquired with the fluorescence
median at 10 2 on FL2-H channel and the percentage of cells with low
fluorescence intensity (considered as apoptotic population) was quantified
using the same marker for control and STS-treated cells. The values
indicated on the Y-axis are the percent apoptotic cells. The data are mean ±
SD of three independent experiments. *P < .05 in comparison between
G1-arrested and unsynchronized cells treated with STS. (B) The activation of
caspase 9 in synchronized SK-N-MC cells treated with STS for 6 hours was
monitored by caspase 9 colorimetric assay. The values on the Y-axis
represent absorbance obtained with the release of pNa by active caspase 9
from its substrate LEDH-pNa. The data are represented as mean ± SD of
three independent experiments. Activity was compared between STS and
untreated corresponding controls. *P < .05; **P < .01.
Figure 5. Inhibition of caspase 9 activity in STS-treated SK-N-MC cells. (A)
Inhibition of caspase 9 activity in unsynchronized and G1-arrested cells
treated with STS for 12 hours in the presence and absence of the caspase 9
inhibitor, Z-LEDH-FMK, assessed by caspase 9 colorimetric assay. Data are
mean ± SD of three experiments. Caspase 9 activity was compared between
cells treated with STS in the presence or absence of inhibitor (*P < .05,
**P < .01). (B) Western blot analysis for expression of PARP (116 kDa)
and cleaved PARP (DPARP) in untreated and STS-treated cells in the
presence or absence of caspase 9 inhibitor. Equal protein loading was con-
firmed with actin.
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led to the complete abrogation of PARP cleavage
(Figure 5B). These results suggest that STS-induced apo-
ptosis in SK-N-MC cells is through this mitochondrial–
caspase 9–mediated pathway and that caspase 9 is the
sole initiator of this apoptotic cascade. Therefore, inhibition
of caspase 9 protects cells from the insult imparted by STS.
Inhibition of the Ubiquitin–Proteasome Pathway Retains
Survivin Expression in G1-Arrested SK-N-MC Cells
Our initial experiments demonstrated differences in ex-
pression of survivin in G1 and G2/M phases and a differential
sensitivity of these arrested populations to STS-induced
apoptosis. We therefore investigated whether retention of
survivin in G1-arrested cultures could protect cells against
STS-mediated apoptosis. The expression of survivin was
monitored by semiquantitative RT-PCR. There was no sig-
nificant difference in survivin expression in the G1 and G2/M
phases at the RNA level (Figure 6A), suggesting that the
differential expression of survivin was a phenomenon that
was regulated posttranscriptionally, either during translation
or degradation of protein. It is known that degradation of
survivin is mediated through the ubiquitin–proteasome
pathway. We studied survivin expression in cells arrested
in G1 phase in the presence of a proteasome inhibitor,
MG132. SK-N-MC cells were treated with 10 mM proteasome
inhibitor MG132 2 hours prior to the G1 arrest, and the
expression of survivin in the G1 phase with and without
MG132 treatment was studied by Western blot analysis. G2/
M-arrested cells were used as a control. We observed that
the addition of MG132 led to the retention of survivin with
72.88% positivity in the G1 phase as compared to the cells
not treated with MG132 that showed undetectable expres-
sion of survivin (Figure 6B). Thus, the differential expression
of survivin observed in the two arrested cell populations is a
posttranscriptionally regulated phenomenon and the degra-
dation of survivin during the G1 phase is mediated through
the ubiquitin–proteasome pathway. To emphasize the im-
portance of survivin in STS-induced apoptosis, we subjected
Figure 6. Inhibition of the ubiquitin –proteasome pathway and survivin expression in G1-arrested SK-N-MC cells. (A) Expression of survivin RNA in
unsynchronized, G1-arrested, and G2/M-arrested populations by semiquantitative RT-PCR. (B) Expression of survivin by Western blotting in SK-N-MC cells
pretreated with the proteasome inhibitor MG132, 2 hours prior to G1 arrest. Histogram plots represent the density of band intensities of survivin normalized with
-actin controls. (C) Western blot analysis for expression of PARP (116 kDa) and cleaved PARP (DPARP) in untreated and STS (12 hours) – treated G1 population
pretreated with MG132. (D) Caspase 9 activity in control and STS-treated unsynchronized and G1-arrested populations. Cells were incubated with MG132 prior G1
arrest followed by STS treatment. The data are mean ± SD of three independent experiments. *P < .05 compared to untreated controls.
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G1-arrested cultures pretreated with MG132 to STS. We
observed no cleavage of PARP in G1-arrested cells wherein
the degradation of survivin was also inhibited (Figure 6C ).
Furthermore, caspase 9 activity was also not observed in
these cells (Figure 6D ), thus confirming that survivin is a vital
antiapoptotic protein that protects SK-N-MC cells against
STS-induced apoptosis and that the abrogation of apoptosis
is due to the inhibition of caspase 9 activity.
Discussion
Major research efforts are aimed at the discovery of
molecular targets that are specifically toxic to tumor cells
and at devising their synergistic combinations. However,
with a few exceptions, tumor cells lack sufficiently specific
targets that would allow them to be killed selectively, and
hence mechanism-based toxicity is an approach of choice.
Cell cycle–mediated drug resistance is best described as
the relative sensitivity of tumor cells to a chemotherapeutic
agent because of its position in the cell cycle. Therefore, a
better understanding of the molecular mechanisms of
action of anticancer drugs or compounds in context with
cell cycle regulation may contribute to the development of
newer strategies for rationally and selectively manipulating
the sensitivity of cancer cells to therapy [17].
In this study, we have demonstrated the differential
responses of the G1- and G2/M-synchronized human neu-
roblastoma cell line SK-N-MC to STS. Although STS, a
broad-spectrum inhibitor of protein kinases, has been used
widely to induce apoptosis in a variety of cell types, the
molecular mechanism(s) is still not clear and is considered
more complex than that of other anticancer drugs [18]. Our
data suggest that STS induces apoptosis through the
mitochondrial-dependent pathway in the human neuroblas-
toma cell line SK-N-MC and that the apoptosis induced is
inhibitable by the presence of the antiapoptotic protein
survivin.
To understand the mechanism by which G2/M cells could
evade the apoptotic insult caused by STS, we assessed the
expression of antiapoptotic proteins Bcl-2 and BclXL because
both these proteins are known to play a crucial role in
protecting cells by blocking apoptosis triggered through the
mitochondrial pathway [19–21]. We observed that the ex-
pression of these molecules was not cell cycle–dependent
and the expression levels were not altered with STS treat-
ment, suggesting that they probably did not play an important
role in the differential response of cells to apoptosis in this
system. A direct link between survivin expression and tumor
cell susceptibility to anticancer drugs such as Taxol has been
reported [22]. As survivin is expressed in a cell cycle–
dependent manner and particularly overexpressed when
the cells transit through the G2/M phase, and our data
revealed specific sensitivity of G1 and relative resistance to
STS of the G2/M population, it was therefore of interest to
examine the expression of survivin in our system. Low levels
of survivin expressed during the G1 phase, but an increased
expression of this protein, were observed in the G2/M
population. Interestingly, localization studies revealed differ-
ences in the expression and distribution of survivin, with
G2/M cells showing more intense nuclear staining for survi-
vin and a yellow cytoplasm indicating colocalization with
tubulin. G1-arrested cells, however, showed weakly positive
staining that was confined to the nucleus. These data
assume importance as expression patterns, and the levels
of survivin play a crucial role in modulating apoptosis.
Studies have reported that survivin plays an important role
in microtubule stability and assembly of normal mitotic
spindle. This may facilitate checkpoint evasion and promote
resistance to chemotherapy in cancer [23]. However, sub-
cellular distribution of survivin has been controversial and
variously described as a microtubule-associated protein or
chromosomal passenger protein [24,25]. Also there have
been reports that survivin may sequester caspases such as
3 and 7 in an inactive state on the microtubules [12].
To perform its antiapoptotic function, survivin requires
phosphorylation on threonine 34 by physically interacting
with p34 cdc-2 [15]. An inhibition of p34 kinase by cdk
inhibitors in mitotically arrested cells results in a loss of
survivin levels with dramatic enhancement in chemothera-
py-induced apoptosis [26]. It is also known that loss of
phosphorylation of survivin results in dissociation of the
survivin–caspase 9 complex on the mitotic apparatus lead-
ing to apoptosis [15]. On these lines, we examined the
expression of cdc-2 in synchronized SK-N-MC cells. We
observed an elevated level of this protein in the G2/M-
arrested cultures, whereas no expression was detected in
G1, suggesting that survivin was phosphorylated by cdc-2 in
SK-N-MC cells in a cell cycle–dependent manner to perform
its antiapoptotic function.
We further reasoned that if survivin was responsible for
protecting G2/M cells against apoptosis by STS, then down-
regulation of survivin should effectively induce cell death. A
dose- and time-dependent decrease in the expression of
survivin was observed with antisense oligonucleotide trans-
fection and treatment of these cells with STS resulted in
apoptosis, suggesting the role of survivin in protecting cells
against apoptosis. The loss of survivin itself in transfected
cells did not affect cellular viability, or induce apoptosis as
previously reported [27–29]. If the mere presence of survi-
vin was the critical factor in promoting cell survival, then
cells arrested in the G1 phase, which showed lower expres-
sion of survivin, should have undergone spontaneous apo-
ptosis. In this context, it is noteworthy that only when the
cells are challenged with an apoptotic insult does the anti-
apoptotic role of survivin to sequester the enzymes in an
inactive state become important. The findings on the precise
mechanism and interaction of survivin with caspases have
been contradictory. Studies have suggested that a direct
interaction of caspases with survivin is essential to inhibit
their activity [12]. A recent report, however, contradicts this
theory, wherein survivin does not bind to caspases but
exerts its effect by physically interacting with other up-
stream molecules such as smac/DIABLO to form a complex
that leads to the inhibition of downstream caspases in
apoptosis induced by Taxol [30]. Marusawa et al. [11] have
described that survivin forms complexes with a cellular
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protein, hepatitis B X-interacting protein (HBXIP), which
binds to procaspase 9, preventing its recruitment to Apaf-1
and suppressing the apoptosis initiated by the mitochondrial
pathway. It is therefore not unreasonable to hypothesize
that survivin plays a similar role in our system, with higher
levels of survivin in the G2/M phase rendering the cells
resistant to STS-induced apoptosis. However, the precise
mechanism by which survivin enhances resistance in G2/M
and the presence of HBXIP-like factor(s) in neuroblastomas
remain to be deciphered.
We further studied the pathway that led to STS-induced
apoptosis in SK-N-MC cells. In accordance with previous
reports in different cell lines [31], we observed that STS
induced a mitochondria-dependent pathway for apoptosis.
Treatment of SK-N-MC cells with STS led to a sequential
breakdown in the membrane potential by 3 hours, followed
by caspase 9 activation that peaked at 6 hours, and, finally,
the cleavage of PARP by 12 hours. However, studies have
reported that apart from caspase 9, other caspases such as
caspases 8 and 2, and proteases such as calpain are also
involved in apoptosis induced by STS [32–34]. Our data also
indicated that activation of caspase 9 was crucial for the
induction of apoptosis, as addition of caspase 9 inhibitor in
unsynchronized and G1-arrested cells completely ablated
the apoptosis induced by STS. Furthermore, there was no
increase in caspase 9 activity in STS-treated G2/M popula-
tions. These data point to the fact that the activation of
caspase 9 alone might be critical for the initiation of the
apoptotic process mediated by STS in SK-N-MC cells. In a
recent study, enhanced sensitivity of G1 cells and the relative
resistance of G2/M cells to a combination therapy of simvas-
tatin and TRAIL were reported in SW480 and H460 cell lines
[35], and the addition of caspase 9 inhibitor could only
partially inhibit apoptosis. One possible explanation for
differences between the findings in this report and our
study could be that TRAIL-induced apoptosis involves
the activation of caspase 8 besides caspase 9, whereas
apoptosis induced by STS in SK-N-MC cells predominantly
triggers the apoptotic pathway involving caspase 9 as the
primary initiator caspase. Survivin expression is regulated
at the transcriptional level with upregulation at G2/M and
downregulation at the G1 phase [36], and G1 transcrip-
tional repressor elements within the survivin promoter
contribute to the cell cycle–dependent expression of the
gene [10]. Interestingly, we found no change in the ex-
pression of the survivin transcript in the different phases of
cell cycle in SK-N-MC cells.
The ubiquitin–proteosome pathway is important in spa-
tial and temporal regulation of the cell cycle through elim-
ination of proteins regulating cell cycle progression through
mitosis. The involvement of this pathway in the regulation of
survivin degradation resulting in the decline in G1 phase
has been reported using specific inhibitors such as MG132
and AllN [37]. We reasoned that if the role of survivin is
restricted to protecting cells on induction of apoptosis, then
the retention of survivin by preventing degradation in G1
cells should protect the cells from apoptosis. We investi-
gated the role of the ubiquitin–proteosome pathway in
survivin degradation. Our data using proteosome inhibitor
MG132 indicated that downregulation of survivin in the G1
phase was indeed due to the degradation of the protein. In
the presence of MG132, the G1-phase cells expressed
survivin and were resistant to STS treatment and also
showed no increase in caspase 9 activity, thereby confirm-
ing a direct correlation between the expression of survivin
and the activation of caspase 9 in SK-N-MC cells treated
with STS.
Taken together, our study demonstrates the differential
responses of G1 and G2/M populations in SK-N-MC cells to
STS-induced apoptosis. The antiapoptotic protein survivin
plays a critical role in imparting resistance to G2/M cells
toward STS that induces apoptosis primarily through the
mitochondrial–caspase 9–mediated pathway. Therefore,
the retention of survivin or the inhibition of caspase 9 led to
a complete abrogation of apoptosis induced by STS in G1
cells. The study also shows that survivin appears to exert its
antiapoptotic effect by inhibiting caspase 9 activity. With cell
cycle–dependent resistance emerging as a new concept in
combination sequential chemotherapy, it is envisaged that
the results from this study will provide information for the
development of tools to facilitate the rational design of
chemotherapy combinations.
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